Gilead Sciences Inc

Gilead Sciences expands oncology with Arcellx acquisition and boosts its HIV lineup using a single‑tablet bictegravir‑lenacapavir regimen, positioning it ahead of competitors.

Gilead Sciences sees split institutional sentiment and modest analyst upside; investors weigh pipeline strength against market volatility and a tight $145 price target.

Gilead Sciences sees a mix of institutional buys and insider sell‑offs; UBS turns bullish amid a strong biopharma outlook, keeping investors watching its near‑52‑week high.

Gilead Sciences faces mixed clinical news: Trodelvy misses breast‑cancer endpoints but Livdelzi shows steady liver‑disease benefits, shaping investor outlook and stock moves.

Gilead Sciences is poised for a paradigm shift after reporting landmark results from the ASCENT-03 trial of Trodelvy, a breakthrough therapy for metastatic triple-negative breast cancer, amidst a bullish market and an insider sale that raises questi…

Gilead Sciences Inc. reports strong Q2 2025 performance, exceeding market estimates with a net income of $1.9 billion and revising its 2025 guidance upwards due to its successful HIV treatment sales.